Endothelial venodilator response in carriers of genetic polymorphisms involved in NO synthesis and degradation

British Journal of Clinical Pharmacology

Volumn 58, Issue 2, 2004, Pages 169-177

  Fricker, Ruth ^a   Hesse, Christiane ^a   Weiss, Johanna ^a   Tayrouz, Yorki ^a   Hoffmann, Michael M ^b   Unnebrink, Kristina ^c   Mansmann, Ulrich ^a   Haefeli, Walter E ^a,d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Endothelial function; Endothelial nitric oxide synthase; NADPH oxidase polymorphism (C242T); Nitric oxide; NOSIII polymorphisms (G894T, T 786C and (CA)n)

Indexed keywords

BRADYKININ; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ARTICLE; BLOOD VESSEL REACTIVITY; CAPACITANCE BLOOD VESSEL; CAUCASIAN; CONTROLLED STUDY; CYBA GENE; DEGRADATION; DINUCLEOTIDE REPEAT; GENE; GENETIC POLYMORPHISM; GENOTYPE; HAND; HARDY WEINBERG DISTRIBUTION LAW; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; NOSIII GENE; POPULATION GENETIC PARAMETERS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYNTHESIS; VASCULAR ENDOTHELIUM; VEIN DILATATION; VENOCONSTRICTION; WILD TYPE;

BRADYKININ; CHOLESTEROL; ENDOTHELIUM, VASCULAR; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; NADPH DEHYDROGENASE; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHOPROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; VASODILATION;

EID: 3843050416     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02130.x     Document Type: Article

References (39)

1. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-12.
2. Whitehead A, FitzGerald GA. Twenty-first century phox - not yet ready for widespread screening. Circulation 2001; 103: 7-9.
3. Marsden P, Heng H, Scherer S, et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993; 268: 17478-88.
4. Nadaud S, Bonnardeaux A, Lathrop M, Soubrier F. Gene structure, polymorphism and mapping of the human endothelial nitric oxide synthase gene. Biochem Biophys Res Commun 1994; 198: 1027-33.
5. Yoshimura M, Yasue H, Nakayama M, et al. A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet 1998; 103: 65-9.
6. Chen W, Srinivasan SR, Elkasabany A, Ellsworth DL, Boerwinkle E, Berenson CS. Combined effects of endothelial nitric oxide synthase gene polymorphism (G894T) and insulin resistance status on blood pressure and familial risk of hypertension in young adults: the Bogalusa Heart Study. Am J Hypertens 2001; 14: 1046-52.
7. Hingorani A, Liang CF, Fatibene J, et al. A common variant of the endothelial nitric oxide synthase (Glu298Asp) is a major risk factor for coronary artery disease in the UK. Circulation 1999; 100: 1515-20.
8. Shimasaki Y, Yasue H, Yoshimura M, et al. Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction. J Am Coll Cardiol 1998; 31: 1506-10.
9. Nakayama M, Yasue H, Yoshimura M, et al. T-786C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999; 99: 2864-70.
10. Nakayama M, Yasue H, Yoshimura M, et al. T-786C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with myocardial infarction, especially without coronary organic stenosis. Am J Cardiol 2000; 86: 628-34.
11. Poirier O, Mao C, Mallet C, et al. Polymorphisms of the endothelial nitric oxide synthase gene - no consistent association with myocardial infarction in the ECTIM study. Eur J Clin Invest 1999; 29: 284-90.
12. Stangl K, Cascorbi I, Laule M, et al. High CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery disease. Pharmacogenetics 2000; 10: 133-40.
13. Miles AM, Bohle DS, Glassbrenner PA, Hansert B, Wink DA, Grisham MB. Modulation of superoxide-dependent oxidation and hydroxylation reactions by nitric oxide. J Biol Chem 1996; 271: 40-7.
14. Griendling KK, Sorescu D, Ushio-Fukai M NAD(P)H oxidase role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.
15. Guzik T, West N, Black E, et al. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 2000; 102: 1744-7.
16. Inoue N, Kawashima S, Kanazawa K, Yamada S, Akita H, Yokoyama M. Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation 1998; 97: 135-7.
17. Gardemann A, Mages P, Katz N, Tillmanns H, Haberbosch W. The p22 phox A640G gene polymorphism but not the C242T gene variation is associated with coronary heart disease in younger individuals. Atherosclerosis 1999; 145: 315-23.
18. Ito D, Murata M, Watanabe K, et al. C242T polymorphism of NADPH oxidase p22 PHOX gene and ischemic cerebrovascular disease in the Japanese population. Stroke 2000; 31: 936-9.
19. Cahilly C, Ballantyne CM, Lim DS, Gotto A, Marian AJ. A variant of p22 (phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis. Circ Res 2000; 86: 391-5.
20. Schneider MP, Erdmann J, Delles C, Fleck E, Regitz-Zagrosek V, Schmieder RE. Functional gene testing of the Glu298Asp polymorphism of the endothelial NO synthase. J Hypertens 2000; 18: 1767-73.
21. Sofowora G, Dishy V, Xie HG, et al. In vivo effects of Glu298Asp endothelial nitric oxide synthase polymorphism. Pharmacogenetics 2001; 11: 809-14.
22. Weiss J, Fricker R, Haefeli WE. Rapid detection of polymorphisms of the nitric oxide cascade. Clin Chem Lab Med 2002; 40: 341-4.
23. Weiss J, Haefeli WE, Gasse C, Hoffmann MM, Weyman J, Gibbs S, Mansmann U, Bärtsch P. Lack of evidence for association of high altitude pulmonary edema and polymorphisms of the NO pathway. High Alt Med Biol 2003; 4: 355-66.
24. Aellig WH. A new technique for recording compliance of human hand veins. Br J Clin Pharmacol 1981; 11: 237-43.
25. Haefeli WE, Srivastava N, Kongpatanakul S, Blaschke TF, Hoffman BB. Lack of role of endothelium-derived relaxing factor in effects of α-adrenergic agonists in cutaneous veins in humans. Am J Physiol 1993; 264: H364-H369.
26. Bedarida GV, Bushell E, Haefeli WE, Blaschke TF, Hoffman BB. Responsiveness to bradykinin in veins of hypercholesterolemic humans. Circulation 1993; 88: 2754-61.
27. Strobel WM, Lüscher TF, Simper D, Linder L, Haefeli WE. Substance P in human hand veins in vivo: tolerance, efficacy, potency, and mechanisms of venodilator action. Clin Pharmacol Ther 1996; 60: 435-43.
28. Dachman WD, Ford GA, Blaschke TF, Hoffman BB. Mechanism of bradykinin-induced venodilation in humans. J Cardiovasc Pharmacol 1993; 21: 241-8.
29. De Lean A, Munson PJ, Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay and physiological dose-response curves. Am J Physiol 1978; 235: E97-E102.
30. Granath B, Taylor RR, van Bockxmeer FM, Mamotte CD. Lack of evidence for association between endothelial nitric oxide synthase gene polymorphisms and coronary artery disease in the Australian Caucasian population. J Cardiovasc Risk 2001; 8: 235-41.
31. Webb DJ. The pharmacology of human blood vessels in vivo. J Vasc Res 1995; 32: 2-15.
32. Mombouli JV, Vanhoutte PM. Kinins and endothelial control of vascular smooth muscle. Annu Rev Pharmacol Toxicol 1995; 35: 679-705.
33. Collier J, Vallance P. Biphasic response to acetylcholine in human veins in vivo: the role of the endothelium. Clin Sci (Lond) 1990; 78: 101-4.
34. Honing ML, Smits P, Morrison PJ, Rabelink TJ. Bradykinin-induced vasodilation of human forearm resistance vessels is primarily mediated by endothelium-dependent hyperpolarization. Hypertension 2000; 35: 1314-8.
35. Bedarida GV, Kim D, Blaschke TF, Hoffman BB. Characterization of an inhibitor of nitric oxide synthase in human-hand veins. Horm Metab Res 1994; 26: 109-12.
36. 3-subunit (C825T) and endothelial nitric oxide synthase (G894T) genes but with serum low density lipoprotein cholesterol. Pharmacogenetics 2001; 11: 307-16.
37. Tsujita Y, Baba S, Yamauchi R, et al. Association analyses between genetic polymorphism of endothelial nitric oxide synthase gene and hypertension in Japanese: The Suita Study. J Hypertens 2001; 19: 1941-8.
38. Leeson CPM, Hingorani AD, Mullen MJ, et al. Glu298Asp endothelial nitric oxide synthase gene polymorphism interacts with environmental and dietary factors to influence endothelial function. Circ Res 2002; 90: 1153-8.
39. Nasreen S, Nabika T, Shibata H, et al. T-786C polymorphism in endothelial NO synthase gene affects cerebral circulation in smokers: Possible gene-environmental interaction. Arterioscler Thromb Vasc Biol 2002; 22: 605-10.